Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. Polzer
Efficacy and Safety of Continuous Every 2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Moderate-To-Severe Plaque Psoriasis in a Randomized Phase 3 Trial (IXORA-P)
British Journal of Dermatology
Dermatology
Medicine
Related publications
Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial
Journal of the European Academy of Dermatology and Venereology
Dermatology
Infectious Diseases
Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
JAMA Dermatology
Dermatology
Medicine
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
SKIN The Journal of Cutaneous Medicine
Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis
Biopharmaceutics and Drug Disposition
Medicine
Pharmacology
Pharmaceutical Science
Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
Journal of the American Academy of Dermatology
Dermatology
Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study
British Journal of Dermatology
Dermatology
Medicine
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
Journal of the American Academy of Dermatology
Dermatology
